Dr. McCormick has a Ph.D. in Analytical Chemistry from Villanova University and over 32 years of R&D experience in the pharmaceutical industry. He has expertise in analytical method development and validation for both drug substance and drug product, and has worked for various organizations including Wyeth Laboratories and DuPont Merck Pharmaceuticals.
He has also been involved in microbicide product development starting with Biosyn, Inc. in 2003 and moving to CONRAD in 2006 where he has overseen and coordinated various aspects of product development such as: preformulation, formulation development, analytical method development, preclinical toxicology and pharmacokinetic studies, stability studies, and process development and manufacturing of drug substance and clinical trial materials. Dr. McCormick is thoroughly familiar with industry regulations and GMPs, and has written the CMC sections of regulatory filings.
- First Phase I double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
- Preclinical evaluation of UC781 microbicide vaginal drug delivery
- A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor